[1] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 中华肝脏病杂志, 2019,27:18-26. [2] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019,70:151-171. [3] 邬步云, 毛慧娟. 选择性血浆置换的研究进展[J]. 中国血液净化, 2019,18:854-857. [4] Nakae H, Igarashi T, Tajimi K. Selective plasma exchange with dialysis in patients with acute liver failure[J]. Ther Apher Dial, 2012,16:467-471. [5] 张行芬, 邓勤智, 王银银, 等. 选择性血浆置换治疗慢加急性肝衰竭肝储备功能的变化趋势及其预后评估价值[J]. 现代实用医学, 2016,28:482-484+561. [6] 高萌, 傅云峰, 张亚男, 等. 重症肝炎患者血浆置换治疗的临床疗效观察[J]. 中国输血杂志, 2016,29:64-67. [7] Shen Y, Wang XL, Wang B, et al. Survival benefits with artificial liver support system for acute-on-chronic liver failure: a time series-based meta-analysis[J]. Medicine (Baltimore), 2016,95:e2506. [8] Hernaez R, Solà E, Moreau R, et al. Acute-on-chronic liver failure: an update[J]. Gut, 2017,66:541-553. [9] Huang K, Ji F, Xie Z, et al. Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis[J]. Sci Rep, 2019,9:16462. [10] Chauhan A, Adams DH, Watson SP, et al. Platelets: no longer bystanders in liver disease[J]. Hepatology, 2016,64:1774-1784. [11] Gallo P, Terracciani F, Di Pasquale G, et al. Thrombocytopenia in chronic liver disease: physiopathology and new therapeutic strategies before invasive procedures[J]. World J Gastroenterol, 2022,28:4061-4074. [12] Qamar AA, Grace ND, Groszmann RJ, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis[J]. Clin Gastroenterol Hepatol, 2009,7:689-695. [13] Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001,33:464-470. [14] 中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 临床肝胆病杂志, 2022,38:767-775. [15] 徐泽锋, 秦铁军, 张宏丽, 等. 不同血小板水平原发性骨髓纤维化患者的临床特征及预后研究[J]. 中华血液学杂志, 2019,40:12-16. [16] Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure[J]. N Engl J Med, 2020,382:2137-2145. [17] Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update[J]. Hepatol Int, 2019,13:353-390. [18] Li X, Li H, Zhu Y, Xu H, et al. PLT counts as a predictive marker after plasma exchange in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Med,2023 ,12(3):851. [19] Jie Y, Gong J, Xiao C, et al. Low platelet to white blood cell ratio indicates poor prognosis for acute-on-chronic liver failure[J]. Biomed Res Int, 2018,2018:7394904. [20] Nowatari T, Murata S, Fukunaga K, et al. Role of platelets in chronic liver disease and acute liver injury[J]. Hepatol Res, 2014,44:165-172. [21] Mussbacher M, Brunnthaler L, Panhuber A, et al. Till death do us part-the multifaceted role of platelets in liver diseases[J]. Int J Mol Sci, 2021,22:3113. [22] Qi X, Wang C. Prognostic value of platelet-to-monocyte ratio for mortality in HBV-related acute-on-chronic liver failure[J]. Int J Gen Med,2024,17:3173-3180. [23] Blasco-Algora S, Masegosa-Ataz J, Gutiérrez-García ML, et al. Acute-on-chronic liver failure: pathogenesis, prognostic factors and management. World J Gastroenterol, 2015,21:12125-12140. [24] Xia Q, Dai X, Zhang Y, et al. A modified MELD model for Chinese pre-ACLF and ACLF patients and it reveals poor prognosis in pre-ACLF patients. PLoS One, 2013,8:e64379. [25] Ripoche J. Blood platelets and inflammation: their relationship with liver and digestive diseases. Clin Res Hepatol Gastroenterol, 2011,35:353-357. [26] Starlinger P, Haegele S, Offensperger F, et al. The profile of platelet α-granule released molecules affects postoperative liver regeneration. Hepatology, 2016,63:1675-1688. [27] Liang C, Takahashi K, Furuya K, et al. Dualistic role of platelets in living donor liver transplantation: Are they harmful. World J Gastroenterol, 2022,28:897-908. [28] Maiwall R, Bajpai M, Singh A, et al. Standard-volume plasma exchange improves outcomes in patients with acute liver failure: a randomized controlled trial. Clin Gastroenterol Hepatol, 2022,20:e831-e854. [29] Xiao LL, Xu XW, Huang KZ, et al. Artificial liver support system improves short-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a propensity score analysis. Biomed Res Int, 2019,2019:3757149. [30] Yang K, Pan Y, Jin L, et al. Low serum soluble transferrin receptor levels are associated with poor prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure. Biol Trace Elem Res, 2023,201:2757-2764. [31] Mao W, Sun Q, Fan J, et al. AST to platelet ratio index predicts mortality in hospitalized patients with hepatitis B-related decompensated cirrhosis. Medicine (Baltimore), 2016,95:e2946. [32] Liu H, Li H, Deng G, et al. Association of AST/ALT ratio with 90-day outcomes in patients with acute exacerbation of chronic liver disease: a prospective multicenter cohort study in China. Frontiers in Medicine, 2024,11. [33] Mirsaeidi M, Peyrani P, Aliberti S, et al. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest, 2010,137:416-420. [34] Brogly N, Devos P, Boussekey N, et al. Impact of thrombocytopenia on outcome of patients admitted to ICU for severe community-acquired pneumonia. J Infect, 2007,55:136-140. [35] Shi Y, Yang Y, Hu Y, et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology, 2015,62:232-242. |